BioAge Labs (BIOA) vs Larimar Therapeutics (LRMR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioAge Labs (BIOA) has outperformed Larimar Therapeutics (LRMR) over the past year, gaining 11.8% versus a loss of 41.7%. BioAge Labs is the larger company by market cap ($279.7 million vs $273.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BIOA | LRMR |
|---|---|---|
| Share price | $6.10 | $2.64 |
| Market cap | $279.74M | $273.73M |
| 1-day change | -2.64% | -4.18% |
| YTD return | -52.68% | -27.82% |
| 1-year return | +11.79% | -41.74% |
| 5-year return | — | -77.31% |
| EPS (TTM) | $-2.39 | $-1.99 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $25.96 | $6.42 |
| 52-week low | $5.04 | $2.63 |
| Distance from 52-week high | -76.52% | -58.96% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +484.58% | +446.49% |
| Average volume | 913.77K | 1.31M |
| Shares outstanding | 45.90M | 103.88M |
| Employees | 60 | 71 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BIOA has outperformed LRMR by 53.5 percentage points over the past year.
About BioAge Labs
BIOA stock →BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging.
Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees
About Larimar Therapeutics
LRMR stock →Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 71 employees
BIOA vs LRMR FAQ
Which is bigger, BioAge Labs or Larimar Therapeutics?
BioAge Labs (BIOA) is larger, with a market capitalization of $279.74M compared with $273.73M for Larimar Therapeutics (LRMR).
Which stock has performed better over the past year, BIOA or LRMR?
BIOA returned +11.79% over the past 12 months, compared with -41.74% for LRMR (price return, excluding dividends). Past performance does not predict future results.
Are BioAge Labs and Larimar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.